Publications by authors named "P Scoppi"

Article Synopsis
  • From March 9 to May 3, 2020, Italy implemented a lockdown due to COVID-19, significantly impacting pediatric emergency room (ER) visits.
  • During the lockdown, ER admissions dropped by 81% compared to the same period in 2019, with air communicable diseases showing the largest decrease.
  • While critical cases (red codes) remained stable, less severe cases (yellow codes) increased, possibly indicating delays in primary care that led to more urgent ER visits.
View Article and Find Full Text PDF

It has been calculated that, on average, 20% of the population should be trained to provide first aid, if a significant reduction of mortality is to be achieved. However, wide dissemination of the principles of emergency care poses a series of difficulties. As a partial solution, we have designed a first aid training course for children aged 8-11 years in their last three courses at primary school.

View Article and Find Full Text PDF

Methylmalonic acidemia (MMA) is an inborn error of organic acid metabolism that occurs in infancy with hypotonia, vomiting, dehydration, lethargy and failure to thrive and is biochemically characterized by metabolic ketoacidosis, hyperammonemia and sometimes hyperglycinemia. It results from deficiency of methylmalonyl-CoA mutase activity due to a defect in the mutase apoenzyme or to deficient function of one of the enzymes required for metabolism of its cofactor vitamin B12. Tubulointerstitial nephritis with progressive impairment of renal function is one of the most frequent long-term complications.

View Article and Find Full Text PDF

Background: Chronic hemolysis, inadequate production of erythropoietin (EPO) or an impaired response of erythroid stem cells to EPO are the main factors of anemia in end-stage renal disease (ESRD) patients. Oxidative damage of red blood cell (RBC) membrane is a well-established cause of chronic hemolysis in hemodialysis (HD) patients. Administration of high-dose recombinant human EPO (rHuEPO) fails to correct anemia in 5 to 10% HD patients although all established factors of resistance to rHuEPO therapy have been previously ruled out or corrected.

View Article and Find Full Text PDF